Sector News

Roche says ‘no thanks’ to megadeals, but don’t count out smaller M&A

January 23, 2019
Life sciences

After two recent, huge tie-ups between Takeda and Shire and Bristol-Myers Squibb and Celgene, megamergers seem to be a biopharma trend. But Roche isn’t interested, its chairman said.

The company is “extremely cautious when it comes to any kind of megamerger,” Roche Chairman Christoph Franz told CNBC at the World Economic Forum in Davos, Switzerland. Not only are huge deals costly, money-wise, but integrating big buyouts costs time and effort that’s “deviating you, maybe from some of your core activities, like, for example, research and development,” Franz told the network.

“That’s the reason why we are focusing on targeted ideas, outside our company, and then creating partnerships,” Franz said, adding that in some cases Roche would do some small- or medium-sized deals.

Franz’s comments come after this month’s $74 billion merger announcement between Bristol-Myers Squibb and Celgene, which ranks among pharma’s largest-ever deals. Also this month, Takeda closed its $62 billion buyout of Shire.

Some industry watchers questioned the motives behind those deals, and insiders at Takeda pushed back against its own proposed buyout. But while the long-term results of those acquisitions remain to be seen, Franz said his company isn’t in a position where it needs to scoop up another large pharma.

“We are benefiting from one of the best innovative pipelines, with new medicines upcoming, so there is no need to focus on acquisitions to create size,” he told CNBC.

It’s a position shared by Pfizer’s new CEO Albert Bourla, who once again swore off a megadeal during his conversation at the J.P. Morgan Healthcare Conference in San Francisco. Asked by JPMorgan analyst Chris Schott about M&A, Bourla said the company has a “unique window of opportunity to get it right with our pipeline and the new launches,” and that he doesn’t want to do a “distractive” deal.

While some top pharma execs plan to stay away from megamergers, that doesn’t mean M&A will slow entirely. Even after Bristol’s megadeal, Eli Lilly struck an $8 billion buyout of cancer specialist Loxo Oncology in early January. And GlaxoSmithKline just closed its $5 billion deal for cancer drugmaker Tesaro.

Market watchers expected an M&A boom in 2018 after U.S. tax reform, but smaller companies’ share prices—and hence valuations—remained high, putting a drag on M&A activity. Now, with lower valuations, a “pent-up demand” for buyouts and other factors, Michael Levesque, senior vice president at Moody’s, previously told FiercePharma he believes there will be an uptick of M&A this year.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.